tci Part B Insider - 2005 Issue 6

Infusion: Check With Your Carrier About Tysabri Coding

Some advise J3590 for new miracle MS drugThe Food and Drug Administration approved a revolutionary new drug for multiple sclerosis, Tysabri, back in November. But providers are still coming to grips with coding for this medication. Physicians will administer Tysabri, also known by the generic name natalizumab, to treat and reduce the frequency of clinical relapses in relapsing forms of MS. The patient receives the drug intravenously every four weeks in either the inpatient or outpatient setting."There's no consistent coding or payment strategy for Tysabri yet," notes Neil Busis, chief of the division of neurology and director...

To read the full article, sign in and subscribe to tci Part B Insider.


Keep pace with evolving Medicare regulations with timely analysis of critical updates interpreted in an easy-to-follow, easy-to-apply format. Your subscription to TCI’s Part B Insider will equip you to navigate code and guideline changes, CCI edits, and revisions to modifiers, the fee schedule, OIG target areas, and more.

  • Current newsletters added each month
  • Fully searchable archives - over 4800 articles
  • ALL years/issues back to 2003 organized by year and issue
  • Codes mentioned in articles are linked to Code Information pages
  • Code Information pages link back to related articles

This feature is currently unavailable for online purchase. For more information, please call 801-770-4203 or Contact Us.

demo
request yours today
 subscribe
start today
 newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.